Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy

[1]  M. Alsharedi,et al.  Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer , 2017, Medical Oncology.

[2]  G. Sica,et al.  Assays for PD-L1 Expression: Do All Roads Lead to Rome? , 2017, JAMA oncology.

[3]  D. Trump,et al.  Targeted therapies in the treatment of urothelial cancers. , 2017, Urologic oncology.

[4]  C. Swanton,et al.  Evolving adoptive cellular therapies in urological malignancies. , 2017, The Lancet. Oncology.

[5]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[6]  R. Bernards,et al.  A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma. , 2017, European urology.

[7]  K. Chamie,et al.  Immune response results of vesigenurtacel-l (HS-410) in combination with BCG from a randomized phase II trial in patients with non-muscle invasive bladder cancer (NMIBC). , 2017 .

[8]  N. Agarwal,et al.  Clinical and translational investigation of pan-HDAC inhibition in advanced urothelial carcinoma (UC). , 2017 .

[9]  J. Datta,et al.  Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398 , 2017, Molecular Cancer Therapeutics.

[10]  Maximilian Burger,et al.  EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. , 2017, European urology.

[11]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[12]  K. Pantel,et al.  Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape , 2017, Nature Reviews Clinical Oncology.

[13]  Swe Swe Myint,et al.  Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2 , 2017, Science Translational Medicine.

[14]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[15]  C. Collins,et al.  Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy , 2017, Scientific Reports.

[16]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  Manuel Hidalgo,et al.  Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Ana-Teresa Maia,et al.  Epigenetic therapy in urologic cancers: an update on clinical trials , 2016, Oncotarget.

[19]  Massimo Cristofanilli,et al.  Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application , 2016, Oncotarget.

[20]  Rajendu Srivastava,et al.  A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Care Costs , 2016, Journal of oncology practice.

[21]  F. Hirsch,et al.  PD‐L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  Jacques Ferlay,et al.  Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. , 2017, European urology.

[23]  D. Berney,et al.  Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Plimack,et al.  A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157 , 2016, Clinical Cancer Research.

[25]  Feng Yue,et al.  FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines , 2016, Scientific Reports.

[26]  Davide Prandi,et al.  Clonal evolution of chemotherapy-resistant urothelial carcinoma , 2016, Nature Genetics.

[27]  Razelle Kurzrock,et al.  Targeted therapies: What have we learned from SHIVA? , 2016, Nature Reviews Clinical Oncology.

[28]  K. Dobbin,et al.  Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation , 2016, Journal of Immunotherapy for Cancer.

[29]  J. Sandbank,et al.  A Harmonization Study for the Use of 22C3 PD‐L1 Immunohistochemical Staining on Ventana’s Platform , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  Tomasz Burzykowski,et al.  Adaptive Randomization of Neratinib in Early Breast Cancer. , 2016, The New England journal of medicine.

[31]  P. Sharma,et al.  Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, phase 1/2 trial , 2016, The Lancet. Oncology.

[32]  Nicole Schechter,et al.  Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma , 2016, Diagnostic Pathology.

[33]  Geoffrey E. Wile,et al.  Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines , 2016 .

[34]  Geoffrey E. Wile,et al.  NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[35]  John D Seigne,et al.  Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. , 2016, The Journal of urology.

[36]  C. Drake,et al.  Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  M. Milowsky,et al.  Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Yusuke Nakamura,et al.  Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  E. Plimack,et al.  Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  R. Knuechel,et al.  Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup , 2016, Oncotarget.

[41]  M. Schoenberg,et al.  Vesigenurtacel-L (HS-410) in the management of high-grade nonmuscle invasive bladder cancer. , 2016, Future oncology.

[42]  Vinay Prasad,et al.  Perspective: The precision-oncology illusion , 2016, Nature.

[43]  J. Weinstein,et al.  Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use , 2016, EBioMedicine.

[44]  M. Ratner.  Genentech's PD-L1 agent approved for bladder cancer , 2016, Nature Biotechnology.

[45]  L. Garraway,et al.  Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. , 2016, JAMA oncology.

[46]  Pornpimol Charoentong,et al.  Computational genomics tools for dissecting tumour–immune cell interactions , 2016, Nature Reviews Genetics.

[47]  A. Markham.  Atezolizumab: First Global Approval , 2016, Drugs.

[48]  Anne M Wallace,et al.  Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. , 2016, The New England journal of medicine.

[49]  Y. Nishimura,et al.  The present status and future prospects of peptide-based cancer vaccines. , 2016, International immunology.

[50]  A. Klinakis,et al.  KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis , 2016, Nature Communications.

[51]  R. Berger,et al.  Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with FGFR3 alterations. , 2016 .

[52]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[53]  S. Groshen,et al.  Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer , 2016, Bladder cancer.

[54]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[55]  T. H. van der Kwast,et al.  Tumor heterogeneity of fibroblast growth factor receptor 3 (FGFR3) mutations in invasive bladder cancer: implications for perioperative anti-FGFR3 treatment. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[56]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[57]  P. Sidaway.  Bladder cancer: Atezolizumab effective against advanced-stage disease , 2016, Nature Reviews Urology.

[58]  T. Sasada,et al.  Prospect and progress of personalized peptide vaccinations for advanced cancers , 2016, Expert opinion on biological therapy.

[59]  R. Bernards,et al.  ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. , 2016, European urology.

[60]  J. Nakhlé,et al.  Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer , 2016, Oncoimmunology.

[61]  A. George,et al.  Novel immunotherapeutic approaches to the treatment of urothelial carcinoma , 2016, Therapeutic advances in urology.

[62]  Fabiana Ramos Vasques,et al.  Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA , 2016, European Journal of Human Genetics.

[63]  G. Sonpavde,et al.  Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. , 2016 .

[64]  Xavier Paoletti,et al.  Precision medicine: lessons learned from the SHIVA trial - Authors' reply. , 2015, The Lancet. Oncology.

[65]  Roland L Dunbrack,et al.  Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. , 2015, European urology.

[66]  A. Hahn,et al.  Precision medicine: lessons learned from the SHIVA trial. , 2015, The Lancet Oncology.

[67]  V. Prasad,et al.  Characteristics of Exceptional or Super Responders to Cancer Drugs. , 2015, Mayo Clinic proceedings.

[68]  S. Naito,et al.  An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy , 2015, Clinical Cancer Research.

[69]  J. Trepel,et al.  Immunotherapies for bladder cancer: a new hope , 2015, Current opinion in urology.

[70]  J. Maranchie,et al.  The Role of Interferon in the Management of BCG Refractory Nonmuscle Invasive Bladder Cancer , 2015, Advances in urology.

[71]  T. Powles,et al.  Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. , 2015, Clinical genitourinary cancer.

[72]  R. Montironi,et al.  Emerging concepts on drug resistance in bladder cancer: Implications for future strategies. , 2015, Critical reviews in oncology/hematology.

[73]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[74]  S. Ikeda,et al.  Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma. , 2015, Cancer treatment reviews.

[75]  J. Tabernero,et al.  Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  G. Steinberg,et al.  Re: Herr et al.: BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: A prospective cohort outcomes study (Urol Oncol 2015; 33: 108.el-108.e4). , 2015, Urologic oncology.

[77]  G. Bartsch,et al.  Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics , 2015, Translational oncology.

[78]  G. Iyer,et al.  Targeted therapy in advanced bladder cancer: what have we learned? , 2015, The Urologic clinics of North America.

[79]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[80]  B. Czerniak,et al.  Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. , 2015, Hematology/oncology clinics of North America.

[81]  A. Kamat,et al.  Nonurothelial bladder cancer and rare variant histologies. , 2015, Hematology/oncology clinics of North America.

[82]  J. Efstathiou,et al.  Bladder preservation strategies. , 2015, Hematology/oncology clinics of North America.

[83]  D. Lamm,et al.  Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer , 2015, Nature Reviews Urology.

[84]  G. Dalbagni,et al.  BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study. , 2015, Urologic oncology.

[85]  M. Loda,et al.  HER2 as a target in invasive urothelial carcinoma , 2015, Cancer medicine.

[86]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[87]  N. Schultz,et al.  Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. , 2015, European urology.

[88]  J. N'Dow,et al.  Significance of MUC1 in bladder cancer , 2015, BJU international.

[89]  A. Ravaud,et al.  Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. , 2015, European journal of cancer.

[90]  A. Poh,et al.  In search of exceptional responders. , 2015, Cancer discovery.

[91]  L. Collette,et al.  Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. , 2015, The Lancet. Oncology.

[92]  A. Bass,et al.  Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. , 2014, The Journal of clinical investigation.

[93]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[94]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[95]  Pamela A Shaw,et al.  Chimeric antigen receptor T cells for sustained remissions in leukemia. , 2014, The New England journal of medicine.

[96]  L. Sequist,et al.  Abstract CT326: Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors , 2014 .

[97]  J. Tabernero,et al.  Abstract CT325: First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors , 2014 .

[98]  C. Dinney,et al.  New insights into subtypes of invasive bladder cancer: considerations of the clinician. , 2014, European urology.

[99]  C. Roberts,et al.  Vulnerabilities of mutant SWI/SNF complexes in cancer. , 2014, Cancer cell.

[100]  Benjamin J. Raphael,et al.  Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin , 2014, Cell.

[101]  S. Gabriel,et al.  Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. , 2014, Cancer discovery.

[102]  Y. Lotan,et al.  The economics of bladder cancer: costs and considerations of caring for this disease. , 2014, European urology.

[103]  Razelle Kurzrock,et al.  Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses , 2014, Clinical Cancer Research.

[104]  T. Sasada,et al.  Personalized peptide vaccine for treatment of advanced cancer. , 2014, Current medicinal chemistry.

[105]  A. Ribas,et al.  The Future of Cancer Therapy: Selecting Patients Likely to Respond to PD1/L1 Blockade , 2014, Clinical Cancer Research.

[106]  J. Witjes,et al.  EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. , 2014, European urology.

[107]  M. Glickman,et al.  The mechanism of action of BCG therapy for bladder cancer—a current perspective , 2014, Nature Reviews Urology.

[108]  S. Gabriel,et al.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.

[109]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[110]  Katherine A. Hoadley,et al.  Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology , 2014, Proceedings of the National Academy of Sciences.

[111]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[112]  M. Berger,et al.  Branched evolution and intratumor heterogeneity of urothelial carcinoma of the bladder. , 2014 .

[113]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[114]  T. Wilbanks,et al.  Implications for Future Risk Management Strategies , 2014 .

[115]  German Cancer.  Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies , 2014 .

[116]  C. Sander,et al.  Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  A. Ashworth,et al.  Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer. , 2013, Cancer discovery.

[118]  I. Ostrovnaya,et al.  Phase II study of everolimus in metastatic urothelial cancer , 2013, BJU international.

[119]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[120]  M. Glickman,et al.  Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. , 2013, Cancer research.

[121]  M. Knowles,et al.  Oncogenic FGFR3 gene fusions in bladder cancer , 2012, Human molecular genetics.

[122]  M. Bhagavan.  The New Hope , 2013 .

[123]  J. Lee,et al.  PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. , 2013, Cancer research.

[124]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[125]  Nola Hylton,et al.  Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[127]  Anne-Marie Welling,et al.  Work in progress. , 2012, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[128]  T. Ørntoft,et al.  Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma , 2012, British Journal of Cancer.

[129]  Mårten Fernö,et al.  A Molecular Taxonomy for Urothelial Carcinoma , 2012, Clinical Cancer Research.

[130]  D. Wood.  Re: international phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. , 2012, The Journal of urology.

[131]  Jens-Peter Volkmer,et al.  Three differentiation states risk-stratify bladder cancer into distinct subtypes , 2012, Proceedings of the National Academy of Sciences.

[132]  K. Kuroiwa,et al.  p300 mediates cellular resistance to doxorubicin in bladder cancer. , 2011, Molecular medicine reports.

[133]  Chang-Hyun Kim,et al.  Animal models for vaccine therapy. , 2012, Advances in experimental medicine and biology.

[134]  Marc E. Lenburg,et al.  Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2011, Breast Cancer Research and Treatment.

[135]  E. Matsumoto.  Training in ureteroscopy: a critical appraisal of the literature , 2011 .

[136]  S. Baba,et al.  A phase I study of personalized peptide vaccination for advanced urothelial carcinoma patients who failed treatment with methotrexate, vinblastine, adriamycin and cisplatin , 2011, BJU international.

[137]  Huanming Yang,et al.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.

[138]  J. Blenis,et al.  The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. , 2011, Trends in biochemical sciences.

[139]  M. Parmar,et al.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[140]  S. Arai,et al.  Dynamic Mobility of Immunological Cells Expressing S100A8 and S100A9 in vivo: A Variety of Functional Roles of the two Proteins as Regulators in Acute Inflammatory Reaction , 2011, Inflammation.

[141]  D. Sgroi,et al.  A Unique Spectrum of Somatic PIK3CA (p110α) Mutations Within Primary Endometrial Carcinomas , 2011, Clinical Cancer Research.

[142]  Y. Lotan,et al.  Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancer , 2011, Cancer.

[143]  Jae K. Lee,et al.  Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. , 2011, Neoplasia.

[144]  P. Olbert,et al.  CA19.9 and CEA in transitional cell carcinoma of the bladder: serological and immunohistochemical findings. , 2010, Anticancer research.

[145]  D. Lamm,et al.  Bacillus Calmette-Guérin with or without interferon α-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer. , 2010, The Journal of urology.

[146]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[147]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[148]  T. Sasada,et al.  Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccines. , 2010, European journal of cancer.

[149]  J. Wolchok,et al.  Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial , 2010, Clinical Cancer Research.

[150]  M. L. Calle,et al.  Genetic susceptibility to distinct bladder cancer subphenotypes. , 2010, European urology.

[151]  S. Rosenberg,et al.  Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells , 2010, Journal of immunotherapy.

[152]  J. McKiernan,et al.  Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG. , 2010, Urologic oncology.

[153]  A. Bohle.  An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer , 2009 .

[154]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[155]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[156]  J. Hamm,et al.  A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma , 2008, Cancer Chemotherapy and Pharmacology.

[157]  Jae K. Lee,et al.  A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery , 2007, Proceedings of the National Academy of Sciences.

[158]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[159]  Stephen J Lippard,et al.  Direct cellular responses to platinum-induced DNA damage. , 2007, Chemical reviews.

[160]  T. Tötterman,et al.  Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. , 2007, The Journal of urology.

[161]  S. Rosenberg,et al.  Increased intensity lymphodepletion and adoptive immunotherapy—how far can we go? , 2006, Nature Clinical Practice Oncology.

[162]  V. Reuter,et al.  Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma , 2006, Clinical Cancer Research.

[163]  A. Bergeron,et al.  Cancer-testis antigen expression in bladder cancer. , 2005, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[164]  Alberto Zolezzi F.  [Do all roads lead to Rome?]. , 2006, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.

[165]  E. Jaffee,et al.  Mechanisms of immune evasion by tumors. , 2006, Advances in immunology.

[166]  Yusuke Nakamura,et al.  Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[167]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[168]  J. Witjes,et al.  Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. , 2005, The Journal of urology.

[169]  C. Goodnow,et al.  Cellular and genetic mechanisms of self tolerance and autoimmunity , 2005, Nature.

[170]  J. Witjes,et al.  920: Bacillus Calmette-Guerin Versus Chemotherapy in the Intravesical Treatment of Carcinoma in Situ: A Meta-Analysis of the Published Results of Randomized Clinical Trials , 2005 .

[171]  C. Klebanoff,et al.  Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. , 2005, Trends in immunology.

[172]  J. Chin,et al.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. , 2004, The Journal of urology.

[173]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[174]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[175]  P. Rouleau,et al.  Proinflammatory Activities of S100: Proteins S100A8, S100A9, and S100A8/A9 Induce Neutrophil Chemotaxis and Adhesion 1 , 2003, The Journal of Immunology.

[176]  P. Rouleau,et al.  Proinflammatory Activities of S 100 : Proteins S 100 A 8 , S 100 A 9 , and S 100 A 8 / A 9 Induce Neutrophil Chemotaxis and Adhesion 1 , 2003 .

[177]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[178]  R. Mcgarry,et al.  Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. , 2000, Journal of clinical epidemiology.

[179]  H. Ozen.  Bladder cancer. , 1998, Current opinion in oncology.

[180]  James Tooley.  TO SELECT OR NOT TO SELECT , 1996 .